Association of adipokines with frailty in heart failure

Association of adipokines with frailty in heart failure

Authors

  • Shinya Fujiki a:1:{s:5:"en_US";s:49:"Department of Cardiovascular Biology and Medicine";}
  • Hiroshi Watanabe
  • Hiroaki Obata
  • Masayoshi Suda
  • Wataru Mitsuma
  • Asako Tomii
  • Katsuyuki Sakai
  • Akifumi Uehara
  • Ippei Shimizu
  • Takeshi Kashimura
  • Kazuyuki Ozaki
  • Tohru Minamino

Keywords:

adipokines, frailty, heart failure, leptin, osteoporosis

Abstract

Background Frailty is a multifactorial physiological syndrome most often associated with age but which has received increasing recognition as a component of chronic illnesses such as heart failure. Patients with heart failure are likely to be frail, irrespective of their age. Adipokine dysregulation, which is associated with frailty, occurs in patients with heart failure. In this study, we tested the hypothesis that adipokines are associated with frailty in patients with heart failure.

Methods Thirty-five patients with heart failure (age, 67 ± 14 years; 25 males; left ventricular ejection fraction, 45 ± 19%) were included. Serum adipokine levels, physical performance, and body composition were measured.

Results Adiponectin and leptin were inversely correlated with grip strength. Adiponectin was inversely correlated with bone mineral density. Leptin was positively correlated with fat mass. Adipokines were not correlated with skeletal muscle mass.

Conclusions Adipokines were associated with frailty in patients with heart failure. Adipokine dysregulation may play a role in the development of frailty in heart failure.

References

(1) Wong LS, van der Harst P, de Boer RA et al. Aging, telomeres and heart failure. Heart failure reviews 2010; 15: 479-86.

(2) Dodson JA, Chaudhry SI. Geriatric conditions in heart failure. Current cardiovascular risk reports 2012; 6: 404-410.

(3) Jha SR, Ha HS, Hickman LD et al. Frailty in advanced heart failure: a systematic review. Heart failure reviews 2015; 20: 553-60.

(4) Denfeld QE, Winters-Stone K, Mudd JO et al. The prevalence of frailty in heart failure: A systematic review and meta-analysis. International journal of cardiology 2017; 236: 283-289.

(5) Zhang Y, Yuan M, Gong M, Tse G et al. Frailty and Clinical Outcomes in Heart Failure: A Systematic Review and Meta-analysis. Journal of the American Medical Directors Association 2018; 19: 1003-1008.e1.

(6) Martín-Sánchez FJ, Rodríguez-Adrada E, Vidan MT et al. Impact of Frailty and Disability on 30-Day Mortality in Older Patients With Acute Heart Failure. The American journal of cardiology 2017; 120: 1151-1157.

(7) Uchmanowicz I, Gobbens RJ. The relationship between frailty, anxiety and depression, and health-related quality of life in elderly patients with heart failure. Clinical interventions in aging 2015; 10: 1595-600.

(8) Vidán MT, Blaya-Novakova V, Sánchez E et al. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. European journal of heart failure 2016; 18: 869-75.

(9) Sepúlveda-Loyola W, Phu S, Bani Hassan E et al. The Joint Occurrence of Osteoporosis and Sarcopenia (Osteosarcopenia): Definitions and Characteristics. J. Am. Med. Dir. Assoc. 2020; 21: 220-225.

(10) Wilson D, Jackson T, Sapey E et al. Frailty and sarcopenia: The potential role of an aged immune system. Ageing research reviews 2017; 36: 1-10.

(11) Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circulation research 2015; 116: 1254-68.

(12) Frantz S, Falcao-Pires I, Balligand JL et al. The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European journal of heart failure 2018; 20: 445-459.

(13) Bellumkonda L, Tyrrell D, Hummel SL et al. Pathophysiology of heart failure and frailty: a common inflammatory origin?. Aging cell 2017; 16: 444-450.

(14) Hubbard RE, O'Mahony MS, Savva GM et al. Inflammation and frailty measures in older people. Journal of cellular and molecular medicine 2009; 13: 3103-9.

(15) Tsai JS, Wu CH, Chen SC et al. Plasma adiponectin levels correlate positively with an increasing number of components of frailty in male elders. PloS one 2013; 8: e56250.

(16) Shibasaki K, Yamada S, Akishita M et al. Plasma Leptin Concentration and Sympathetic Nervous Activity in Older Adults With Physical Dysfunction. Journal of the Endocrine Society 2018; 2: 1040-1049.

(17) Ma L, Sha G, Zhang Y et al. Elevated serum IL-6 and adiponectin levels are associated with frailty and physical function in Chinese older adults. Clinical interventions in aging 2018; 13: 2013-2020.

(18) Wiedermann CJ, Beimpold H, Herold M et al. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. Journal of the American College of Cardiology 1993; 22: 1897-901.

(19) Leyva F, Anker SD, Egerer K et al. Hyperleptinaemia in chronic heart failure. Relationships with insulin. European heart journal 1998; 19: 1547-51.

(20) Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-62.

(21) Ouchi N, Parker JL, Lugus JJ et al. Adipokines in inflammation and metabolic disease. Nature reviews. Immunology 2011; 11: 85-97.

(22) Emami A, Saitoh M, Valentova M et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur. J. Heart Fail. 2018; 20: 1580-1587.

(23) Loncar G, Bozic B, von Haehling S et al. Association of adiponectin with peripheral muscle status in elderly patients with heart failure. Eur. J. Intern. Med. 2013; 24: 818-23.

(24) Motie M, Evangelista LS, Horwich T et al. Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome. Experimental and therapeutic medicine 2014; 8: 181-186.

(25) McEntegart MB, Awede B, Petrie MC et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. European heart journal 2007; 28: 829-35.

(26) Karayannis G, Giamouzis G, Tziolas N et al. Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology 2013; 64: 173-80.

(27) Naot D, Musson DS, Cornish J. The Activity of Adiponectin in Bone. Calcified tissue international 2017; 100: 486-499.

(28) Tsutamoto T, Tanaka T, Sakai H et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. European heart journal 2007; 28: 1723-30.

Downloads

Published

01-07-2021

Issue

Section

ORIGINAL ARTICLES

How to Cite

1.
Fujiki S, Watanabe H, Obata H, Suda M, Mitsuma W, Tomii A, et al. Association of adipokines with frailty in heart failure. Acta Biomed [Internet]. 2021 Jul. 1 [cited 2024 Jul. 17];92(3):e2021195. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/9228